Opexa Therapeutics (OPXA) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Opexa Therapeutics Reports Second Quarter 2015 Financial Results and Provides Corporate Update
August 12, 2015 4:02 PM EDTTHE WOODLANDS, Texas--(BUSINESS WIRE)-- Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies for autoimmune disorders including multiple sclerosis (MS) and neuromyelitis optica (NMO), today reported financial results for the three months ended June 30, 2015 and provided an update on the Companys recent corporate developments.
Recent highlights include:
Clinical and Operational Highlights
The Phase 2b clinical trial of Tcelna® (imilecleucel-T) in Secondary Progressive Multiple Sclerosis (SPMS) (Abili-T trial) continued to advance in the second quarter. Top line data is expected... More